Th1/Th17 cytokine profiles are associated with disease severity and exacerbation frequency in COPD patients

Yan Yu
Peking University People's Hospital
Lili Zhao
Peking University People's Hospital
Yu Xie
Peking University People's Hospital
Yu Xu
Peking University People's Hospital
Weike Jiao
Ningde Municipal Hospital Affiliated to Fujian Medical University
Jianhui Wu
Ningde Municipal Hospital Affiliated to Fujian Medical University
Xinyu Deng
Ningde Municipal Hospital Affiliated to Fujian Medical University
Guiju Fang
Ningde Municipal Hospital Affiliated to Fujian Medical University
Qing Xue
Ningde Municipal Hospital Affiliated to Fujian Medical University
Yali Zheng
Xiang'an Hospital of Xiamen University
Zhancheng Gao (zcgao@bjmu.edu.cn)
https://orcid.org/0000-0002-8495-9221

Research

Keywords: Chronic obstructive pulmonary disease, acute exacerbation, Th1 cytokines, Th17 cytokines, therapeutic

Posted Date: March 3rd, 2020

DOI: https://doi.org/10.21203/rs.3.rs-15769/v1

Abstract

Background T helper (Th) cell cytokine imbalances have been associated with the pathophysiology of chronic obstructive pulmonary disease (COPD), including the Th1/Th2 and Th17/Treg paradigms. Clarifying cytokine profiles during COPD acute exacerbation (AE) and their relationships with clinical manifestations would help in understanding the pathogenesis of disease and improve clinical management.

Methods Patients admitted to the hospital with AEs of COPD from January 2017 to August 2017 were included in this study, and follow-up was conducted after discharge (every 30 days, for a total of 120 days). Sputum samples of patients at different time points (including at admission, discharge, and follow-up) were collected, and sputum cytokine profiling (12 cytokines in total) was performed using a Luminex assay. Clinical data of patients were collected by a unified electronic medical record form.

Results A total of 87 patients with COPD were enrolled, aged 72 ± 8.5 years, among whom 1, 12, 32, and 42 cases exhibited GOLD stage I, II, III, and IV, respectively. According to the cytokine profiles at admission, patients were divided into three clusters by a k -means clustering algorithm, namely, Th1 high Th17 high (n=26), Th1 low Th17 low (n=56), and Th1 high Th17 low (n=5), which revealed distinct clinical characteristics. Patients with Th1 high Th17 low profile had a significantly longer length of non-invasive ventilation time and length of hospital stay than patients with Th1 high Th17 high profile (7 vs. 0 days, 22 vs. 11 days, respectively, $p < 0.05$), and had the highest AE frequency. Sputum levels of Th17 cytokines (IL-17A, IL-22, and IL-23) during AE were negatively correlated with AE frequency in the last 12 months ($r = -0.258$, -0.289 and -0.216, respectively, $p < 0.05$). Moreover, decreased sputum IL-17A levels were independently associated with increased AE frequency, whith an OR (95% CI) of 0.975 (0.958 - 0.993) and a $p = 0.006$.

Conclusion Th1/Th17 imbalance during AE is associated with the severity of COPD. Decreased Th17 cytokine expression is correlated with increased AE frequency. The Th1/Th17 balance may be a specific target for the therapeutic manipulation of COPD.

Trial registration: ClinicalTrials.gov ID: NCT03236480.

Background

Chronic obstructive pulmonary disease (COPD) is a major global health issue affecting approximately 10% of people over 40 years old [1]. It is a chronic airway inflammatory disease characterized by persistent and poorly reversible airflow limitation.

Different T-helper (Th) cell cytokines have been identified in the pathogenesis of COPD. Th1 cytokines, such as interferon γ (IFN-γ), tumor necrosis factor α (TNF-α) and interleukin 2 (IL-2), are critical pro-inflammatory cytokines that activate macrophages, NK cells, and CD8 + T cells. They drive neutrophilic inflammation, promote pathogen clearance, and even lead to tissue destruction [2, 3]. Th2 cytokines (e.g,

IL-4, IL-5, IL-13, and IL-17E) are associated with immunity against extracellular parasites, allergy and airway hypersensitivity [2]. IL-4 mediates the production of IgE in B cells. IL-5 and IL-17E promote the differentiation, recruitment and survival of eosinophils in the airway, whereas IL-13 promotes the induction of airway hypersensitivity [2, 4]. Recent studies revealed that COPD patients with high a Th2 cytokine response had increased eosinophil counts, increased bronchodilator responsiveness and improved response to ICS treatment [5–7]. IL-6, IL-1β, IL-21, and IL-23 are essential for the differentiation, function and survival of Th17 cells, which produce mainly IL-17A, IL-21, IL-22, and IL-23 [8]. IL-17A and IL-22 induce epithelial cells to produce antimicrobial peptides, chemokines, and granulocyte growth factors to promote neutrophil accumulation in the airway [9]. T regulatory cells (Treg) suppress the proliferation and cytokine production of other T cells through the creation of anti-inflammatory cytokines, such as IL-10 and TGF-β [10]. Several studies have shown an impaired balance between Treg cytokines and Th17 cytokines in COPD. Increased Th17 cytokines and decreased Treg cytokines were found in COPD patients in the stable stage, and Th17 and Treg cytokines were both evaluated during an exacerbation, with an increased Th17/Treg cytokine ratio [11–14].

Studies have shown that high levels of TNF-α and IL-17A are negatively correlated with pulmonary function in COPD [12, 15, 16]. However, therapies targeting these cytokines (infliximab and etanercept against TNF-α and CNTO 6785 against IL-17) have not shown promising effects in COPD patients, such as an improvement in pulmonary function and symptom scores or a decrease in exacerbations [17–21]. Notably, an increase in infection and respiratory tract cancers was observed in these trials. Therefore, further studies are needed on the profiles of cytokines and the relationship between cytokines and clinical manifestations in COPD patients.

This study aimed to determine the airway Th cell cytokine profiles during COPD exacerbation and decubation, and the relationships between cytokines and clinical features.

Methods

Study populations

Patients diagnosed with acute exacerbations of COPD and hospitalized in Ningde City Hospital and Peking University People's Hospital from January 2017 to August 2017 were consecutively enrolled in the study (ClinicalTrials.gov ID, NCT03236480).

COPD was diagnosed according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [22]: (1) a history of exposure to cigarette smoke or other risk factors for the disease; (2) symptoms such as dyspnea, chronic cough and/or sputum production; and (3) a post-bronchodilator fixed ratio of forced expiratory volume in one second (FEV1) / forced vital capacity (FVC) less than 0.70. COPD severity was assessed using spirometry criteria outlined by the GOLD guidelines [22]: 1) GOLD stage 1, FEV1% predicted is greater than or equal to 80%; 2) GOLD stage 2, FEV1% predicted is greater than or equal to 50%, but less than 80%; 3) GOLD stage 3, FEV1 % predicted is greater than or equal to 30%, but less than 50%; and 4) GOLD stage 4, FEV1% predicted is less than 30%. An exacerbation of

COPD was defined as an acute event characterized by a worsening of the patient's respiratory symptoms that were beyond normal day-to-day variations and led to a change in medication [22].

The exclusion criteria were the presence of significant respiratory disease other than COPD, such as asthma, pulmonary tuberculosis, interstitial lung disease, or lung cancer.

For patients hospitalized before May 1st, 2017 (cohort A), clinical data during hospitalization were collected using a standard electronic medical record. For patients enrolled after May 1st 2017 (cohort B), additional follow-up for 120 days was requested. Follow-up forms, including smoking status, clinical symptom, and medication questions, were completed every 30 days. Before collecting any data, written informed consent was obtained from all patients. The Ethics Committee of Peking University People's Hospital approved the study. The screening and follow-up process is shown in Figure 1.

Sputum sample collection and preservation

Spontaneous sputum samples were collected in the first 24 hours after admission and 24 hours before discharge. In cohort B, sputum samples were also collected every 30 days during the 120-day follow-up. Sputum specimens were discharged into sterile cups and then incubated with 1× volume 0.1% dithiothreitol (DTT) at 37℃ for 30 minutes. After that, samples were mixed with an equal volume (to the DTT solution) of sterile normal saline, rocked for 5 minutes, and then centrifuged at 12000 rpm for 10 minutes at room temperature [23, 24]. The supernatants were stored at -80 °C and transported in dry ice to the laboratory in Peking University People's Hospital.

Cytokine measurements

Twelve cytokines, including Th1 (TNF-α, IFN-γ, and IL-2), Th2 (IL-4, IL-5, and IL-17E), Th17 (IL-6, IL-17A, IL-21, IL-22, and IL-23) and Treg (IL-10) cytokines were measured using a Luminex Human Magnetic Assay Kit (LXSAHM-12; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Mean fluorescence intensity calculated from duplicates of each sample was collected using a Luminex 200 System (Luminex, Austin, TX, USA). The detection sensitivity was 1000 fluorochromes per microsphere. A seven-point standard curve including the blank, was used to calculate sample cytokine concentrations. The lower limits of detection (LOD) for specific analytes ranged from 0.98-92.78 pg/ml based on the manufacturer's specifications.

Statistical analysis

We restricted our analyses to cytokines for which < 30% of samples were below the LOD [25]. The percentages of measurements below the LOD for the 12 cytokines were as follows: TNF-α, 0.4%; IFN-γ, 23.5% (47.1% at admission); IL-2, 37.6%; IL-4, 7.3%; IL-5, 1.7%; IL-17E, 2.6%; IL-6, 0.4%; IL-17A, 0%; IL-21, 29.5% (42.5% at admission); IL-22, 15.4%; IL-23, 0.9%; and IL-10, 28.6% (32.2% at admission). Thus, IL-2 levels at all 6-time points and IFN-γ, IL21, and IL-10 levels at admission were excluded from further analysis. Then we imputed values below the LOD by a value of one-half of the LOD [26]. After imputation,

the normality of the imputed data was assessed using the Kolmogorov-Smirnov test. Subsequently, to evaluate whether the Th cell cytokines in sputum could be partitioned into clusters with distinct cytokine phenotypes, *k*-means partitional clustering [27] was employed based on the cytokine levels of all subjects at admission. The elbow method [28] was used to determine the optimal *k* number of clusters using the R package “NbClust” [29]. Spearman's rank correlation was performed to analyze the associations between cytokine levels and clinical parameters. Binary logistic regression was used to determine the risk factors affecting the frequency of acute exacerbations.

Generally, categorical variables are presented as numbers (percentages), parametric continuous variables are presented as the mean ± SD, and nonparametric continuous variables are presented as median and interquartile ranges (25th and 75th percentiles). Continuous nonparametric data were analyzed using the Mann-Whitney U or Kruskal-Wallis test and continuous parametric data were analyzed using Student’s t-test or one-way analysis of variance (ANOVA). All categorical data were analyzed using a chi-square or Fisher’s exact test. All analyses were performed in SPSS Statistics (version 25.0). A two-sided *p*-value <0.05 was considered statistically significant; confidence intervals (CIs) were set at 95%.

Results

Population characteristics

A total of eighty-seven patients (82 men and five women) were included in the study, 64 in cohort A and 23 in cohort B, with a mean age of 72 ± 8.5 years. Individually, 13, 32, and 42 patients were classified as GOLD stages 1~2, 3, and 4, respectively. A total of 16 patients (18.4%) received assisted ventilation during hospitalization, and two died (2.3%). As shown in Table 1, there were no significant differences in age, sex, smoking history, or the prevalence of comorbidities and complications among patients at different GOLD stages, except for the incidence of non-invasive ventilation, which was significantly higher in patients at GOLD stage 4.

Sputum levels of T helper cell cytokines during hospitalization

To understand changes in Th cell cytokines during COPD exacerbations, we compared the levels of cytokines at admission and discharge. As shown in Figure 2, the levels of Th1 (TNF-α), Th2 (IL-17E), and Th17 (IL-17A and IL-22) cell cytokines at admission were significantly higher than those at discharge, and IL-22 and TNF-α exhibited the most significant changes with 2.8-fold and 2.0-fold increases, respectively. IL-10 content was low both during AEs and at the 120-day follow-up, indicating a defective IL-10 response in COPD patients, as previously reported [16]. No significant differences in sputum levels of cytokines were observed among different GOLD stages. Likewise, no significant differences were observed in clinical classifications based on age, sex, or disease complications such as respiratory failure, cor pulmonale, etc. (all $p > 0.05$, data not shown).

Cluster analysis revealed three distinct Th cell cytokine profiles

To evaluate whether sputum samples from all subjects at admission could be partitioned into clusters with distinct Th cell cytokine profiles, we utilized a *k*-means clustering algorithm. This approach yielded three separate cytokine clusters (as shown in Figure 3), with 26, 56, and five patients in cluster 1, cluster 2, and cluster 3, respectively.

The Kruskal-Wallis test revealed that 7 out of 8 cytokines were significantly different among the clusters (all $p < 0.01$, as shown in Additional file 1). We further performed pairwise comparisons. As shown in Figure 4, Th1 (TNF-α), Th2 (IL-17E), and Th17 (IL-6, IL-17A, and IL-22) cell cytokine expression significantly differed from each other. In cluster 3, the highest levels of TNF-α and IL-6 (~25.9-fold and ~107.7-fold compared to those in the lowest cluster, respectively) and the lowest level of IL-17A (~0.2-fold compared to that in the highest cluster) were observed. Meanwhile, the highest levels of IL-17A, IL-22, and IL-17E (approximately 4.3-fold, 2.7-fold, and 3.5-fold compared to those in the lowest cluster, respectively) were observed in cluster 1. Notably, the levels of IL-6, a cytokine that promotes Th17 cell differentiation, were highest in cluster 3 ($p < 0.001$), while the primary effector cytokines of Th17 cells, IL-17A and IL-22, were the lowest ($p < 0.001$). The data indicated IL-17A and IL-22 deficiencies in the COPD patients of cluster 3. In general, we identified three distinct Th cell cytokine profiles through cluster analysis, which were termed "$Th1_{high}Th17_{high}$" (cluster 1), "$Th1_{low}Th17_{low}$" (cluster 2), and "$Th1_{high}Th17_{low}$" (cluster 3).

We assumed that differential cytokine expression is associated with different clinical characteristics. We compared the clinical data among these three clusters (Table 2 and Figure 3). As shown in Table 2, the overall distributions of GOLD stages in distinct clusters were similar to each other. However, patients in cluster 3 ("$Th1_{high}Th17_{low}$") suffered from the most extended length of hospital stay and the longest length of non-invasive ventilation (Kruskal-Wallis test, $p = 0.019$ and $p = 0.011$, respectively). Moreover, they had the lowest body mass index (BMI) and the highest AE frequency (Kruskal-Wallis test, $p = 0.002$, and $p = 0.035$, respectively).

Spearman correlation analysis between clinical manifestations and cytokines revealed that AE frequency was negatively correlated with sputum levels of Th17 cytokines (IL-17A, IL-22, and IL-23) and Th2 cytokines (IL-17E) (all $p < 0.05$), as shown in Figure 5. In addition, the level of IL-6 was positively correlated with the length of non-invasive ventilation ($r = 0.254$, $p < 0.05$).

Th17 cytokine expression levels were related to AE frequency in COPD patients

We further analyzed the correlations between sputum levels of cytokines and AE frequency. As shown in Table 3, in patients with high AE frequency (more than two times in the previous 12 months), the levels of IL-17A and IL-22 were significantly lower than those in patients with a relatively low AE frequency (≤ 2 times in the previous 12 months) ($p = 0.036$ and 0.019). Table 3 also lists other variables that exhibited significant differences between patients with a high AE frequency and those with a low AE frequency, including the incidence of chronic cor pulmonale, GOLD stage, modified British Medical Research Council (mMRC) scores, 6-minute walking test results, COPD assessment test (CAT) scores and the levels of IL-23,

and we also included the levels of IL-17E which were correlated with AE frequency. We further performed backward stepwise logistic regression to analyze the independent relationship between Th17 cytokines (IL-17A and IL-22) and high AE frequency. As shown in Table 3, reduced sputum levels of IL-17A were an independent risk factor for high AE frequency, with an OR (95% CI) of 0.975 (0.958-0.993) and a p = 0.006.

Levels of IL-17A and IL-22 over the 120-day follow-up

We assumed that reduced expression levels of IL-17A and IL-22 indicated higher frequencies of AE. Values of four-time points during the 120-day follow up were further assessed. As shown in Figure 6, patients who revealed lower levels of IL-22 and IL-17A suffered a higher incidence of AE in the next 30 days, although without statistical significance. The tendency remained the same for IL-22 at all four-time points of follow-up, while IL-17A only maintained the trend 90 days after discharge.

Discussion

In the present study, we characterized the Th cell cytokine profiles, including those for Th1, Th2, and Th17 cells and Treg, in sputum samples of 87 COPD patients during acute exacerbations. We identified three distinct Th cell cytokine profiles during AE, including $Th1_{high}Th17_{high}$, $Th1_{low}Th17_{low}$, and $Th1_{high}Th17_{low}$ profiles, which exhibited significantly different clinical outcomes. The $Th1_{high}Th17_{low}$ profile during AE was associated with increased duration of NPPV, lengths of hospital stay, and AE frequency. Moreover, decreased sputum IL-17A levels were independently associated with increased AE frequency to more than twice per year. We also identified that defective IL-22 expression in COPD might persist and indicate acute exacerbations in the short term.

Consistent with previous studies, our study showed that high expression of Th1 cytokines during exacerbations was related to poor prognosis, which might be due to the role of Th1 cytokines in promoting inflammatory responses, mucus secretion, and tissue destruction. We found that the levels of TNF-α exhibited the most significant change during exacerbation among Th1 cytokines. As an essential pro-inflammatory cytokine, TNF-α plays a critical role in the stable stage and during AE of COPD. An animal study showed that TNF-α was associated with cigarette-induced airway macrophage and neutrophil influx, production of matrix metalloproteinase (MMP), and the development of emphysema [30]. There is an increase in the levels of TNF-α in both induced sputum and serum in patients with stable COPD, with a further rise during exacerbations [15, 31]. Singh et al. [15] found that elevated serum levels of TNF-α in patients with stable COPD were related to reduced predicted FEV1%. The evidence above indicates that TNF-α is closely correlated with disease progression and prognosis in COPD patients. However, in patients with either stable COPD or exacerbations, anti-TNF therapies have not been proven effective and might be associated with increased pulmonary infections and lung cancer [17–20].

Another pro-inflammatory cytokine, IL-6, was related to the poor prognosis of COPD patients in our study. IL-6 is a recognized biomarker of inflammation. Hurst et al. [32] found that levels of IL-6 in the serum and

airway during exacerbation were correlated with other inflammatory markers, such as leukocyte count, myeloperoxidase (MPO) and c-reactive protein (CRP). Pinto-Plata et al. [33] reported that the levels of IL-6 were significantly correlated with changes in dyspnea and FEV1 in patients hospitalized for exacerbation of COPD. Our results are consistent with the above studies, implying that severe inflammatory response during exacerbation leads to a poor clinical outcome.

We determined Th17 cytokine levels in COPD patients during and after exacerbation and found that IL-17A and IL-22 contents increased significantly during an exacerbation, which was consistent with results from other studies [11, 34, 35]. Furthermore, we found that COPD severity was correlated with Th17 cytokine levels in sputum during exacerbation and those who cannot produce sufficient IL-17A and IL-22 suffer from a severe course, implying that Th17 cytokines play a protective role during exacerbation. This finding seems to be contradictory with previous studies, in which Th17 cytokines play a harmful role in the pathogenesis and progression of COPD, such as being involved in neutrophilic inflammation in the lung [35], alveolar cell apoptosis [36], airway fibrosis [37], emphysema development [38] and pulmonary function decline [12, 16, 34]. Most exacerbations of COPD are caused by infection. Nontypeable Haemophilus influenzae (NTHi) and Streptococcus pneumonia (S. pneumonia) are the most common bacteria associated with COPD exacerbation.[39] Th17 cells play an important role in host defense against pathogens in the lung, including bacteria, viruses and fungi. IL-17A and IL-22, the primary cytokines produced by Th17 cells, induce neutrophil and macrophage recruitment, antimicrobial peptides production and airway epithelial repair during infection [40, 41]. It has been confirmed in animal models and human immune cells that Th17 cells and cytokines are activated and participate in host defense and clearance of pathogens during infection with NTHi and S. pneumonia.[42–45] Therefore, our results suggest that Th17 cytokine levels increase during exacerbation and participate in the host defense against pathogens, and patients with low levels of Th17 cytokines have a prolonged course and increased severity of disease conditions.

The correlation between Th17 cytokines and AE frequency in COPD patients has not been investigated in previous studies. Our findings showed that a high AE frequency is correlated with decreased sputum Th17 cytokine levels during exacerbation and that a low level of IL-17A is a risk factor for frequent AE. We infer that the anti-infection function of Th17 cytokines can reduce the risk of infection in patients with COPD, thereby reducing AE frequency. This hypothesis is supported by clinical data from patients with psoriasis who were treated with secukinumab, an anti-IL-17A antibody, who showed an elevated rate of infection, especially respiratory disease [46]. Furthermore, an increased rate of exacerbation was observed in another clinical trial in which patients with COPD were treated with CNTO 6785, another anti-IL-17 antibody [21]. These results imply that the role of Th17 cytokines in COPD is quite complicated. Although the Th17 cytokine response is related to chronic pulmonary inflammation and airway remodelling in COPD patients, it is vital to resist pathogens and prevent infection and frequent exacerbation. Previous studies that found that Th17 cytokines promoted disease progression were based mostly on results in the stable stage. Our studies showed that decreased levels of IL-17A and IL-22 during exacerbations were related to course severity and AE frequency. This result implies that Th17 cytokines

might play different roles in the stable stage and exacerbation stage, and subsequent studies need to pay attention to this difference.

Our study showed that patients with $Th1_{high}Th17_{low}$ profiles had a worse prognosis than those with $Th1_{high}Th17_{high}$ patterns. This result suggests that among patients who had high levels of Th1 cytokines, those who could produce sufficient Th17 cytokines would have better clinical outcomes than those who could not. In other words, patients with a Th1/Th17 imbalance have the worst clinical manifestations. We hypothesize that the Th1/Th17 imbalance is due mainly to some COPD patients having an impaired ability to produce a Th17 response (especially IL-17A and IL-22 production), which results in increased susceptibility to infection, thereby leading to increased exacerbation severity and frequency. Andelid et al. [47] found that IL-17 concentrations in the blood were markedly lower in stable COPD patients than in non-smoker control subjects; the group of Barczyk et al.[48] reported lower levels of IL-17 in the sputum of COPD patients than in that of chronic bronchitis patients. This finding suggests that the Th17 pathway could be impaired in COPD patients. Pichavant et al.[43] found an increase in IL-17 and IL-22 levels in BAL and lung lysates of air-exposed mice but not in those of CS (cigarette smoke) -exposed mice after S. pneumonia challenge, and they found the same defect in PBMCs from COPD patients. Furthermore, in that study, they found reduced levels of IL-17-producing NK and NKT cells and IL-22-producing conventional T cells, NK cells, NKT-like cells, and Lin-negative cells in CS-exposed mice. All of the above evidence, as well as our study, suggests that COPD patients have different abilities to produce Th17 responses, which may be one of the reasons for poor clinical trial results, and further clinical trials should take this fact into account to select patients who may benefit from anti-Th17 cytokine treatment.

The limitation of our study is that we did not determine the cytokine profiles in the sputum of healthy people, and the difference in Th17 cytokine levels between COPD patients and healthy people could not be clarified. Our follow-up did not have enough patients or a sufficient period, so further study is needed.

Conclusion

Our study determined the cytokine profiles in the sputum of patients with COPD. We identified three distinct Th cell cytokine profiles during AE, namely $Th1_{high}Th17_{high}$, $Th1_{low}Th17_{low}$, and $Th1_{high}Th17_{low}$ patterns, which exhibited significantly different clinical outcomes. Th1/Th17 imbalance during AE is associated with the severity of COPD. Sufficient Th17 cytokine responses (production of IL-17A and IL-22, especially IL-17A) can reduce the frequency and severity of the exacerbation. The Th1/Th17 balance may be a specific target for therapeutic manipulation of COPD.

Abbreviations

6MWD, 6-minute walking distance; AE, acute exacerbation; BMI, body mass index; CAT, COPD assessment test; COPD, chronic obstructive pulmonary diseases; CRP, c-reactive protein; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; GOLD, global initiative for chronic obstructive lung disease; IFN, interferon; IL, interleukin; mMRC, modified British Medical Research Council; MMP, matrix

metalloproteinase; MPO, myeloperoxidase; NTHi, Nontypeable *Haemophilus influenza*; *S. pneumonia*, *Streptococcus pneumonia*; Th, T-helper; TNF, tumor necrosis factor; Treg, T regulatory cells

Declarations

Ethics approval and consent to participate: The study was approved by the Ethics Committee of Peking University People's Hospital. The approval number is 2016PHB202-01. Informed written consent was obtained from all participants.

Consent for publication: Not applicable.

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: The study was funded by the National Key Research and Development Program of China (2016YFC0903800), the National Science and Technology Major Project of China (2017ZX10103004-006), the Medical Technology Promotion Research Project of Ningde City, Fujian Province (2109901) and the Research project for Young Scientists of Fujian Provincial Health Commission (2017-2-95).

Authors' contributions:

YZ and ZG conceived and designed this study. WJ, JW, XD, GF and QX were in charge of the acquisition of samples and clinical data. YY, LZ, YX and YX conducted the experiment and statistical analysis, and wrote and edited the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors thank staff members of Ningde City Hospital for assistance with study participants enrollment and data collection.

Additional Files

Additional file 1. Table S1. Levels of cytokines at admission of the patients in the three clusters. (DOCX 15 kb)

References

1. Barnes PJ, Burney PG, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, Wouters EF. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076.
2. Shannon AC, Matthew JR, Gary AK. T-Cell Immunity. In: Ronald H, Edward JB, Leslie ES, Helen EH, Jeffrey IW, John A, Mohamed S, editors. Hematology: Basic Principles and Practice. PA: Elsevier;

2018. p. 221-39.
3. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2009;41:631-8.
4. Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018;18:454-66.
5. Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS, Postma DS, Lenburg ME, Spira A, Woodruff PG. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191:758-66.
6. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, investigators E. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44:1697-700.
7. de Llano LP, Cosio BG, Iglesias A, de Las Cuevas N, Soler-Cataluna JJ, Izquierdo JL, Lopez-Campos JL, Calero C, Plaza V, Miravitlles M, et al. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach. Int J Chron Obstruct Pulmon Dis. 2018;13:591-601.
8. Le Rouzic O, Pichavant M, Frealle E, Guillon A, Si-Tahar M, Gosset P. Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur Respir J. 2017;50: 1602434.
9. Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: where do we stand? Mediators Inflamm. 2013;2013:413735.
10. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239-44.
11. Ding GZ, Li WS. The expressions and significance of APN, D-D, IL-17 and hs-CRP in patients with acute exacerbation of chronic obstructive pulmonary disease. Eur Rev Med Pharmacol Sci. 2018;22:6463-8.
12. Zou Y, Chen X, Liu J, Zhou DB, Kuang X, Xiao J, Yu Q, Lu X, Li W, Xie B, Chen Q. Serum IL-1beta and IL-17 levels in patients with COPD: associations with clinical parameters. Int J Chron Obstruct Pulmon Dis. 2017;12:1247-54.
13. Imani S, Salimian J, Fu J, Ghanei M, Panahi Y. Th17/Treg-related cytokine imbalance in sulfur mustard exposed and stable chronic obstructive pulmonary (COPD) patients: correlation with disease activity. Immunopharmacol Immunotoxicol. 2016;38:270-80.
14. Wang H, Ying H, Wang S, Gu X, Weng Y, Peng W, Xia D, Yu W. Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease. Clin Respir J. 2015;9:330-41.
15. Singh S, Verma SK, Kumar S, Ahmad MK, Nischal A, Singh SK, Dixit RK. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers. Immunol Lett. 2018;196:1-10.
16. Jiang S, Shan F, Zhang Y, Jiang L, Cheng Z. Increased serum IL-17 and decreased serum IL-10 and IL-35 levels correlate with the progression of COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2483-94.
17. Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21:234-8.

18. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:926-34.
19. Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EF. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration. 2008;76:275-82.
20. Aaron SD, Vandemheen KL, Maltais F, Field SK, Sin DD, Bourbeau J, Marciniuk DD, FitzGerald JM, Nair P, Mallick R. TNFalpha antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013;68:142-8.
21. Eich A, Urban V, Jutel M, Vlcek J, Shim JJ, Trofimov VI, Liam CK, Kuo PH, Hou Y, Xiao J, et al. A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease. COPD. 2017;14:476-83.
22. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347-65.
23. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax. 1997;52:498-501.
24. Kelly MM, Keatings V, Leigh R, Peterson C, Shute J, Venge P, Djukanovic R. Analysis of fluid-phase mediators. Eur Respir J. 2002;20 Suppl 37:24-39.
25. Lubin JH, Colt JS, Camann D, Davis S, Cerhan JR, Severson RK, Bernstein L, Hartge P. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect. 2004;112:1691-6.
26. Hornung RW, Reed LD. Estimation of Average Concentration in the Presence of Nondetectable Values. Appl Occup Environ Hyg. 1990;5:46-51.
27. Steinhaus H. Sur la division des corps matériels en parties. Bull Acad Polon Sci Cl III. 1956;4:801-4.
28. Ketchen DJ, Shook CL. The Application of Cluster Analysis in Strategic Management Research: An Analysis and Critique. Strat Mgmt J. 1996;17:441-58.
29. Charrad M, Ghazzali N, Boiteau V, Niknafs A. NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set. J Stat Softw. 2014;61:1-36.
30. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2004;170:492-8.
31. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:349-55.
32. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:71-8.

33. Pinto-Plata VM, Livnat G, Girish M, Cabral H, Masdin P, Linacre P, Dew R, Kenney L, Celli BR. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007;131:37-43.
34. Zheng X, Zhang L, Chen J, Gu Y, Xu J, Ouyang Y. Dendritic cells and Th17/Treg ratio play critical roles in pathogenic process of chronic obstructive pulmonary disease. Biomed Pharmacother. 2018;108:1141-51.
35. Roos AB, Sethi S, Nikota J, Wrona CT, Dorrington MG, Sanden C, Bauer CM, Shen P, Bowdish D, Stevenson CS, et al. IL-17A and the Promotion of Neutrophilia in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192:428-37.
36. Chang Y, Al-Alwan L, Audusseau S, Chouiali F, Carlevaro-Fita J, Iwakura Y, Baglole CJ, Eidelman DH, Hamid Q. Genetic deletion of IL-17A reduces cigarette smoke-induced inflammation and alveolar type II cell apoptosis. Am J Physiol Lung Cell Mol Physiol. 2014;306:L132-43.
37. Yanagisawa H, Hashimoto M, Minagawa S, Takasaka N, Ma R, Moermans C, Ito S, Araya J, Budelsky A, Goodsell A, et al. Role of IL-17A in murine models of COPD airway disease. Am J Physiol Lung Cell Mol Physiol. 2017;312:L122-30.
38. Kurimoto E, Miyahara N, Kanehiro A, Waseda K, Taniguchi A, Ikeda G, Koga H, Nishimori H, Tanimoto Y, Kataoka M, et al. IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice. Respir Res. 2013;14:5.
39. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355-65.
40. Rathore JS, Wang Y. Protective role of Th17 cells in pulmonary infection. Vaccine. 2016;34:1504-14.
41. McAleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev. 2014;260:129-44.
42. Sharan R, Perez-Cruz M, Kervoaze G, Gosset P, Weynants V, Godfroid F, Hermand P, Trottein F, Pichavant M, Gosset P. Interleukin-22 protects against non-typeable Haemophilus influenzae infection: alteration during chronic obstructive pulmonary disease. Mucosal Immunol. 2017;10:139-49.
43. Pichavant M, Sharan R, Le Rouzic O, Olivier C, Hennegrave F, Remy G, Perez-Cruz M, Kone B, Gosset P, Just N, Gosset P. IL-22 Defect During Streptococcus pneumoniae Infection Triggers Exacerbation of Chronic Obstructive Pulmonary Disease. EBioMedicine. 2015;2:1686-96.
44. Le Rouzic O, Kone B, Kluza J, Marchetti P, Hennegrave F, Olivier C, Kervoaze G, Vilain E, Mordacq C, Just N, et al. Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response. Respir Res. 2016;17:94.
45. King PT, Lim S, Pick A, Ngui J, Prodanovic Z, Downey W, Choong C, Kelman A, Baranyai E, Francis M, et al. Lung T-cell responses to nontypeable Haemophilus influenzae in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131:1314-21.e14.
46. van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T. Secukinumab long-term safety experience: A pooled analysis of 10 phase II

and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83-98.e4.

47. Andelid K, Tengvall S, Andersson A, Levanen B, Christenson K, Jirholt P, Ahren C, Qvarfordt I, Ekberg-Jansson A, Linden A. Systemic cytokine signaling via IL-17 in smokers with obstructive pulmonary disease: a link to bacterial colonization? Int J Chron Obstruct Pulmon Dis. 2015;10:689-702.
48. Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med. 2003;97:726-33.

Tables

Table 1 Clinical characteristics of the patients according to GOLD stages.

	GOLD stage 1, 2 (n = 13)	GOLD stage 3 (n = 32)	GOLD stage 4 (n = 42)	*p*-value
	74.08 ± 6.291	73.22 ± 9.882	70.40 ± 7.908	0.239
	12 (92.3%)	29 (90.6%)	41 (97.6%)	0.354
	21.17 ± 2.43	20.93 ± 2.69	22.00 ± 3.16	0.281
	27.88 ± 21.60	27.72 ± 24.89	36.26 ± 25.91	0.289
	7 (53.8%)	14 (43.8%)	12 (28.6%)	0.181
litus	1 (7.7%)	4 (12.5%)	7 (16.7%)	0.764
ıia	0 (0.0%)	0 (0.0%)	3 (7.1%)	0.379
rt disease	5 (38.5%)	6 (18.8%)	13 (31.0%)	0.323
ɛy disease	0 (0.0%)	2 (6.3%)	0 (0.0%)	0.265
ɔn frequency ɔnths	2 (1-4)	2 (1-5)	3 (2.75-6.25)	0.094
ıtory failure	3 (23.1%)	7 (21.9%)	6 (14.3%)	0.631
atory failure	3 (23.1%)	9 (28.1%)	11 (26.2%)	0.940
ventilation	0 (0.0%)	2 (6.3%)	13 (31%)	0.004
bation	0 (0.0%)	0 (0.0%)	2 (4.8%)	0.641
ɔrtality	0 (0.0%)	0 (0.0%)	2 (4.8%)	0.641
pital stay, days	13 (9-20)	11 (10-15)	13 (11-16)	0.367

Pulmonary function parameters (FEV1/FVC and FEV1) are values after the use of a bronchodilator at the acute stage.

GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in one second.

Table 2 Clinical characteristics of the patients in three clusters.

	Cluster 1 (n = 26)	Cluster 2 (n = 56)	Cluster 3 (n = 5)	*p*-value
	71.54 ± 8.941	72.38 ± 8.616	70.00 ± 6.364	0.799
	24 (92.3%)	54 (96.4%)	4 (80.0%)	0.188
	20.67 ± 3.49	22.13 ± 2.21	17.51 ± 3.59	0.002
	27.17 ± 24.39	34.04 ± 23.95	32.00 ± 40.87	0.518
	10 (38.5%)	23 (41.1%)	0 (0.0%)	0.237
litus	2 (7.7%)	10 (17.9%)	0 (0.0%)	0.412
ıia	0 (0.0%)	3 (5.4%)	0 (0.0%)	0.622
rt disease	9 (34.6%)	13 (23.2%)	2 (40.0%)	0.402
ey disease	2 (7.7%)	0 (0.0%)	0 (0.0%)	0.199
	51.4 ± 9.9 [a]	47.9 ± 9.5 [b]	45.0 ± 14.7	0.271
d	32.8 (25.3-45.7) [a]	29.5 (18.1-45.1) [b]	27.4 (19.2-47.2)	0.230
	4 (15.4%)	8 (14.3%)	1 (20.0%)	0.889
	9 (34.6%)	22 (39.3%)	1 (20.0%)	0.810
	13 (50.0%)	26 (46.4%)	3 (60.0%)	0.823
on frequency onths	2 (1-3)	3 (2-5.75)	4 (1-7)	0.040
ıtory failure	3 (15.4%)	12 (21.4%)	0 (0.0%)	0.651
atory failure	7 (26.9%)	15 (26.8%)	1 (20.0%)	1.000
ventilation	3 (11.5%)	9 (16.1%)	3 (60.0%)	0.050
-invasive ays	0 (0-0)	0 (0-0)	7 (0-18)	0.011
bation	1 (3.8%)	0 (0.0%)	1 (20.0%)	0.037
ortality	1 (3.8%)	0 (0.0%)	1 (20.0%)	0.037
pital stay, days	11 (9-14.25)	13 (11-15.75)	22 (15-23.5)	0.019

Pulmonary function parameters (FEV1/FVC and FEV1) are values after the use of a bronchodilator at acute stage.

[a] n = 22; [b] n = 51.

GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; TNF, tumor necrosis factor; IL, interleukin.

Table 3 Univariate analysis and multivariate regression to identify independent factors that correlated with high AE frequency.

Variable	Univariate analysis		Multivariate logistic regression	
	P	OR (95% CI)	*P*	OR (95% CI)
Age, yrs	0.084	1.047 (0.993-1.104)		
Male	0.991	1.010 (0.160-6.379)		
Chronic cor pulmonale	0.005	5.647 (1.517-21.016)		
GOLD 4	0.003	4.000 (1.591-10.056)		
mMRC score > 2	<0.001	5.500 (2.143-14.118)		
6MWD < 250m	0.001	4.705 (1.858-11.912)		
CAT score > 20	<0.001	8.140 (2.859-23.178)	<0.001	12.965 (3.293-51.049)
IL-17A, pg/ml	0.036	0.986 (0.973-0.999)	0.006	0.975 (0.958-0.993)
IL-22, pg/ml	0.019	0.984 (0.970-0.997)		
IL-23, pg/ml	0.039	0.998 (0.997-1.000)		
IL-17E, pg/ml	0.114	0.999 (0.998-1.000)		

GOLD, global initiative for chronic obstructive lung disease; mMRC, modified British Medical Research Council; 6MWD, 6-minute walking distance; CAT, COPD assessment test; IL, interleukin.

Figures



Figure 1

Flowchart of the study population.



Figure 2

Levels of cytokines at admission and discharge. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. TNF, tumor necrosis factor; IFN, interferon; IL, interleukin.



Figure 3

Grouping using k-means clustering (A) and clinical features across the three clusters (B)~(D). According to the levels of cytokines at admission, 87 patients were divided into three clusters (cluster 1, cluster 2 and cluster 3, painted in red, green and blue, respectively, in the figure) using a k-means clustering algorithm.



Figure 4

Levels of cytokines at admission across the three clusters. TNF, tumor necrosis factor; IL, interleukin.



Figure 5

Spearman correlation analysis between clinical features and the levels of cytokines at admission. r is the correlation coefficient. IL, interleukin.



Figure 6

Levels of Th17 cytokines during the 120-day follow-up.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.docx